The Ministry of Health has decided to refund a drug used in the treatment of advanced Parkinson's disease. This decision enables Poland to join the European countries in which the infusion therapies for years to help patients with the disease to live with dignity. The formulation of levodopa and carbidopa in the form of a gel, provided in the form of enteric infusion by means of a special pump in a drug program is available from the May 1 year.
Medicine with advanced Parkinson's disease is finally available in Poland
Advanced Parkinson's disease is characterized by increasingly effective response to pharmacological treatment. Today's medicine in the treatment of disease offers DBS (Deep Brain Stimulation - brain pacemaker implantation), and infusion therapies. In Poland, so far only been reimbursed DBS, and because of the limitations associated with its use (eg due to illness is often accompanied by depression, or age above 70 years of age), close to 50 percent. patients not eligible for surgery.
Infusion therapies or subcutaneous apomorphine infusions or enteral administration Duodopy, extend and significantly improve the quality of life of patients. Their use leads to improvements in the overall physical condition of the patient expressed a prolonged state without troublesome dyskinesia, while reducing the time spent in the off state.
Infusion therapy is a therapeutic options for the treatment of advanced Parkinson's disease. Previously they were not available for Polish patients. Duodopy providing an opportunity for a better quality of life for those patients in whom current pharmacological treatment does not give a sufficiently good control of motor symptoms, and for various reasons they are not eligible for surgery of deep brain stimulation. Information about the refund is very good news for both patients and the medical community - said dr. n med. Dariusz Koziorowski, neurologist, President of the Polish Society of Parkinson's Disease and other movement disorders.
One of the main objectives of the Foundation Parkinson was a struggle for Polish patients access to infusion therapy. - As the foundation for five years fought for it, to equalize the chances of patients in Poland with those in Europe and let them dignity, all possible methods to roll his personal battle with advanced disease - added Jadwiga Pawlowska-Machajek, president of the Parkinson's Foundation.
Parkinson's disease is one of the most common degenerative diseases of the nervous system and begins between 40 and 70 years of age. As a result of disease or damage to the disappearance of nerve cells are located in a small but very important part of the human brain - the substantia nigra. These cells are responsible for the production of dopamine. It causes a significant loss of motor symptoms of Parkinson's disease, among others, bradykinesia, muscle rigidity and tremor at rest. The first period of the disease - "honeymoon" takes on average 3-5 years and has a good and stable response to pharmacological treatment with no side effects. Symptomatic, however, are the symptoms that occur later, ie. Problems with speech, drooling, difficulty swallowing food and liquids, problems with writing, contracture legs, trouble sleeping, nightmares, personality changes, depression, changes in intellectual and frustrating freezes, or inability detachment of the foot from the ground and move any further.
Despite 200 years of describe Parkinson's disease are still not able to clearly diagnose the disease-causing factors. Probably in its formation involves various genetic and environmental factors.
Medicine with advanced Parkinson's disease is finally available in Poland
Advanced Parkinson's disease is characterized by increasingly effective response to pharmacological treatment. Today's medicine in the treatment of disease offers DBS (Deep Brain Stimulation - brain pacemaker implantation), and infusion therapies. In Poland, so far only been reimbursed DBS, and because of the limitations associated with its use (eg due to illness is often accompanied by depression, or age above 70 years of age), close to 50 percent. patients not eligible for surgery.
Infusion therapies or subcutaneous apomorphine infusions or enteral administration Duodopy, extend and significantly improve the quality of life of patients. Their use leads to improvements in the overall physical condition of the patient expressed a prolonged state without troublesome dyskinesia, while reducing the time spent in the off state.
Infusion therapy is a therapeutic options for the treatment of advanced Parkinson's disease. Previously they were not available for Polish patients. Duodopy providing an opportunity for a better quality of life for those patients in whom current pharmacological treatment does not give a sufficiently good control of motor symptoms, and for various reasons they are not eligible for surgery of deep brain stimulation. Information about the refund is very good news for both patients and the medical community - said dr. n med. Dariusz Koziorowski, neurologist, President of the Polish Society of Parkinson's Disease and other movement disorders.
One of the main objectives of the Foundation Parkinson was a struggle for Polish patients access to infusion therapy. - As the foundation for five years fought for it, to equalize the chances of patients in Poland with those in Europe and let them dignity, all possible methods to roll his personal battle with advanced disease - added Jadwiga Pawlowska-Machajek, president of the Parkinson's Foundation.
Parkinson's disease is one of the most common degenerative diseases of the nervous system and begins between 40 and 70 years of age. As a result of disease or damage to the disappearance of nerve cells are located in a small but very important part of the human brain - the substantia nigra. These cells are responsible for the production of dopamine. It causes a significant loss of motor symptoms of Parkinson's disease, among others, bradykinesia, muscle rigidity and tremor at rest. The first period of the disease - "honeymoon" takes on average 3-5 years and has a good and stable response to pharmacological treatment with no side effects. Symptomatic, however, are the symptoms that occur later, ie. Problems with speech, drooling, difficulty swallowing food and liquids, problems with writing, contracture legs, trouble sleeping, nightmares, personality changes, depression, changes in intellectual and frustrating freezes, or inability detachment of the foot from the ground and move any further.
Despite 200 years of describe Parkinson's disease are still not able to clearly diagnose the disease-causing factors. Probably in its formation involves various genetic and environmental factors.